Is Boswellia Safe for Your Kidneys?

Boswellia appears safe for kidneys at standard supplement doses, based on the clinical trial data available so far. Multiple human studies have tracked kidney function markers over weeks to months and found no significant changes. That said, the research base is still fairly small, and two published case reports describe acute kidney injury in people taking Boswellia products. The picture is more nuanced than a simple thumbs-up or thumbs-down, and a few factors can tilt the risk profile in ways worth understanding.

What Human Trials Show About Kidney Function

The most direct evidence comes from clinical trials that measured kidney biomarkers in participants taking Boswellia over time. In a randomized, double-blind, placebo-controlled trial of a Boswellia serrata extract for knee osteoarthritis, researchers tracked blood urea nitrogen and serum creatinine at the start and after 90 days. Both markers stayed essentially flat in the Boswellia group, with creatinine holding steady at about 0.8 mg/dL and BUN barely moving. No clinically meaningful changes were noted in any blood chemistry panel.¹

A separate open-label safety study looked at a combination supplement containing turmeric, Boswellia, and sesame in healthy adult volunteers. Kidney markers including estimated glomerular filtration rate, BUN, creatinine, creatinine clearance, and the BUN-to-creatinine ratio all remained normal throughout the study period, with no significant shifts at any of the four measurement time points.²

These results are reassuring, but they come with caveats. The trials enrolled relatively healthy people (or people with osteoarthritis but no kidney disease), used standardized extracts at recommended doses, and ran for only a few months. They tell you that typical supplementation in generally healthy adults does not appear to strain the kidneys in the short to medium term. They do not tell you much about long-term use, very high doses, or people whose kidneys are already compromised.

Animal Evidence for Kidney Protection

An interesting wrinkle in the Boswellia-and-kidneys story is that most of the animal research actually points toward kidney protection, not kidney harm. Several studies have deliberately damaged rat kidneys with toxins or disease models and then tested whether Boswellia could limit the damage.

In one study, rats given carbon tetrachloride (a potent toxin) developed roughly a three-fold spike in serum creatinine and a two-fold jump in urea, classic signs of kidney distress. Rats that also received Boswellia serrata gum resin saw those markers drop back to levels that were statistically indistinguishable from healthy control animals.³ Another team found that Boswellia powder given to diabetic rats reduced blood sugar, lowered kidney damage markers, increased key protective proteins like albumin, and prevented structural abnormalities in kidney tissue. The supplement also cut oxidative stress in the kidneys by lowering markers of cell damage and boosting the body’s own antioxidant defenses.⁴

Similar protective effects have been seen against kidney damage caused by chemotherapy drugs and by ischemia-reperfusion injury, the type of damage that occurs when blood flow to the kidney is temporarily cut off and then restored. In that scenario, Boswellia dialed down inflammatory signaling molecules and bolstered antioxidant levels in both the kidney and the liver in a dose-dependent way.⁵

These are animal studies, not human trials, so you cannot assume the same effects translate directly. But they consistently suggest that the boswellic acids in Boswellia tend to reduce kidney inflammation and oxidative damage rather than cause it, at least in the doses tested. The contradiction between this protective trend and the rare human injury reports is part of what makes this topic worth looking at carefully.

Reported Cases of Kidney Injury

Despite the generally favorable trial data and animal research, at least two published case reports have documented acute kidney injury linked to Boswellia. These are important to know about even though case reports represent individual events rather than population-level risk.

In one case, a 72-year-old woman developed acute kidney injury after taking Boswellia serrata capsules for just eight days. She had been using them to manage radiation necrosis. Her symptoms resolved after she stopped the supplement and received treatment in an emergency department. The authors noted that the injury may have been related to a high dose and emphasized the need for medical supervision.⁶

A second case involved a 41-year-old man who developed fever, nausea, vomiting, and acute kidney injury within hours of ingesting Boswellia serrata bark powder. A kidney biopsy revealed dense inflammation with immune cells consistent with acute interstitial nephritis, an allergic-type inflammatory reaction in the kidney tissue. The authors described this as the first biopsy-proven case of interstitial nephritis linked to Boswellia and specifically flagged the risks of unprocessed herbal preparations.⁷

Two cases from the entire published literature is a very small signal. But a few details stand out. The first patient was elderly and was taking capsules at what was described as a high dose. The second was consuming raw bark powder, not a standardized extract. Both factors may matter: age-related kidney reserve is lower in older adults, and unprocessed plant material can deliver unpredictable doses of active compounds along with contaminants or irritants that a standardized extract would remove. Interstitial nephritis is also sometimes an immune-mediated reaction that can happen with essentially any new substance an individual is sensitive to. It does not necessarily mean Boswellia is inherently toxic to the kidneys.

Why the Kidneys Get High Exposure to Boswellic Acids

One reason kidney safety deserves special attention with Boswellia is that the kidneys happen to be a primary destination for boswellic acids once they are absorbed. A pharmacokinetic study using a lecithin-based delivery form of Boswellia extract found that the highest tissue uptake of boswellic acids occurred in the kidneys and liver. With the enhanced-absorption formulation, levels of the key compounds KBA and AKBA in kidney tissue jumped up to 24-fold compared to standard extract, and other boswellic acids showed two- to seven-fold increases.⁸

This matters for two reasons. On the protective side, it may explain why Boswellia is so effective at reducing kidney inflammation in animal studies: the active compounds concentrate right where the inflammation is. On the risk side, it means the kidneys are seeing more of the compound than most other organs. If someone takes a very high dose or uses a high-bioavailability formulation, kidney tissue gets a proportionally larger hit. Enhanced-absorption products, which are increasingly popular because they improve the traditionally poor bioavailability of boswellic acids, may amplify both the benefits and the risks.

How Boswellia Behaves in People With Existing Kidney Disease

For people who already have chronic kidney disease, the evidence is limited but not absent. A small study in CKD patients tested a supplement combining curcumin and Boswellia serrata and found the combination was safe, tolerable, and helped improve levels of an inflammatory marker.⁹ That is a cautiously positive result, though the combination makes it difficult to attribute effects to Boswellia alone.

A separate animal study that evaluated Boswellia in models of both acute and chronic kidney failure was less encouraging. Boswellia showed only partial protective effects against both types of kidney failure and, unlike some other herbal agents tested, did not demonstrate antioxidant activity in that particular experimental setup.¹⁰ The contrast with the other animal studies described earlier probably reflects differences in the models used, the doses, and the form of Boswellia tested. It is a useful reminder that “Boswellia protects kidneys” is an oversimplification of a more mixed body of evidence.

If you have CKD or reduced kidney function, the key concern is that your kidneys clear waste less efficiently, and any substance that concentrates in kidney tissue could theoretically accumulate to higher levels than it would in someone with fully functioning kidneys. No study has specifically tested whether boswellic acid clearance is impaired in CKD, but the pharmacokinetics suggest a reason for extra caution. Standard clearance of the main boswellic acid (11-keto-beta-boswellic acid) runs at roughly 296 mL/min, well above what the kidneys alone would filter, suggesting the liver plays a major role in elimination.¹¹ Still, any reduction in kidney or liver function could slow overall clearance.

Drug Interactions Worth Knowing About

One underappreciated risk with Boswellia and the kidneys is indirect: it can interfere with how your body processes other drugs. Lab studies have found that extracts from multiple Boswellia species act as broad inhibitors of the major cytochrome P450 enzymes that metabolize drugs. That includes CYP 2C9, which breaks down widely used NSAIDs like ibuprofen, naproxen, and diclofenac. Frankincense extracts inhibited CYP 2C9 at concentrations as low as 1 to 5 micrograms per milliliter.¹²

Why does this matter for your kidneys? NSAIDs are one of the most common causes of drug-induced kidney injury, and their kidney risk increases when blood levels rise. If Boswellia slows the metabolism of an NSAID you are also taking, the NSAID could build up in your system, raising the likelihood of gastrointestinal bleeding and kidney damage. People often take Boswellia precisely because they have joint pain or inflammatory conditions, which are the same conditions for which NSAIDs are commonly prescribed. The overlap makes this interaction particularly relevant in practice. If you take Boswellia alongside prescription anti-inflammatory drugs, it is worth flagging this with your doctor.

The Quality Control Problem

A significant variable in Boswellia safety is the product itself. The biopsy-proven case of interstitial nephritis described earlier involved raw bark powder, not a standardized extract. That distinction matters. Unprocessed plant material can contain a wide and inconsistent mix of compounds, contaminants, and irritants that are removed or controlled in standardized preparations.

This is part of a broader issue with plant-based supplements. Research on supplement quality has found that active ingredient levels can differ dramatically from what the label states and vary widely between products. Supplements sold online may also be adulterated with undeclared prescription drugs. Products containing herbal mixtures rather than single-herb preparations have been more frequently associated with moderate and severe adverse reactions.¹³

For Boswellia specifically, this means the safety profile established in clinical trials using characterized, standardized extracts may not apply to the random bottle of boswellia you pick up at a market or order from an unfamiliar online seller. When formal safety testing of a well-characterized water-soluble Boswellia extract was conducted in rats over 90 days, no signs of toxicity appeared in body weight, food intake, organ weights, thyroid hormones, or any pathology assessment at doses up to 500 mg/kg/day.¹⁴ Similarly, a standardized methanolic extract of a related species, Boswellia sacra, produced no significant changes in kidney or liver toxicity biomarkers in rats over 28 days at doses up to 100 mg/kg.¹⁵ The safety of the extract depends heavily on what that extract actually is.

Higher-Bioavailability Formulations and What They Mean for Risk

Boswellic acids are notoriously hard to absorb from the gut. This has driven the development of enhanced formulations using lecithin complexes, nanoparticles, and other delivery technologies. These products can dramatically increase how much boswellic acid reaches the bloodstream and, consequently, the kidneys.

A lecithin-based delivery form boosted kidney tissue levels of the most active boswellic acids by up to 24 times compared to an ordinary extract.⁸ If you are using one of these enhanced-absorption products, you are effectively taking a much higher dose as far as your kidneys are concerned, even if the milligram count on the label looks similar to a standard extract. The clinical trials showing stable kidney function used specific formulations at specific doses, and those results may not transfer cleanly to a product engineered for much higher bioavailability.

Nanoparticle-based Boswellia formulations have also emerged in research. One study found that Boswellia-chitosan nanoparticles could reduce kidney damage markers and regenerate tubular tissue in a toxicity model with effectiveness comparable to vitamin E.¹⁶ These are experimental, but they illustrate the direction the field is moving: toward forms that deliver more active compound to tissue. That is probably good news for therapeutic effectiveness and potentially fine for kidney safety at controlled doses, but it narrows the margin for error if someone takes too much.

Practical Guidance for Supplement Users

If you are considering Boswellia or already taking it, a few practical points emerge from the evidence. Standard doses of reputable, standardized Boswellia serrata extracts have not shown kidney toxicity in any human trial to date. The risk appears to increase with high doses, unprocessed or raw preparations, advanced age, pre-existing kidney disease, and concurrent use of NSAIDs or other drugs metabolized by CYP enzymes.

Choosing a product from a manufacturer that provides third-party testing and lists a standardized boswellic acid content reduces your exposure to the quality-control risks that plague the supplement market more broadly. If you take any prescription medications, the enzyme-inhibition data suggest it is worth mentioning Boswellia to your prescriber, even though this interaction has not been widely studied in humans. And if you develop unexplained nausea, reduced urine output, or swelling while taking Boswellia, stopping the supplement and getting your kidney function checked is a reasonable step. In both published case reports, the kidney injury resolved once the supplement was discontinued.